Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.33 - $10.44 $9,652 - $305,370
-29,250 Reduced 48.11%
31,550 $12,000
Q3 2022

Nov 14, 2022

SELL
$0.92 - $11.16 $177,810 - $2.16 Million
-193,272 Reduced 76.07%
60,800 $52,000
Q2 2022

Aug 15, 2022

BUY
$1.02 - $1.83 $259,153 - $464,951
254,072 New
254,072 $295,000
Q1 2022

May 16, 2022

SELL
$1.06 - $2.1 $103,969 - $205,976
-98,084 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$2.05 - $3.2 $88,783 - $138,588
-43,309 Reduced 30.63%
98,084 $201,000
Q3 2021

Nov 15, 2021

BUY
$2.54 - $4.07 $113,718 - $182,217
44,771 Added 46.34%
141,393 $435,000
Q2 2021

Aug 16, 2021

BUY
$2.57 - $4.85 $54,576 - $102,994
21,236 Added 28.17%
96,622 $393,000
Q1 2021

May 17, 2021

BUY
$1.9 - $2.82 $143,233 - $212,588
75,386 New
75,386 $186,000
Q4 2020

Feb 16, 2021

SELL
$1.15 - $2.4 $52,894 - $110,388
-45,995 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$1.11 - $1.68 $122,280 - $185,073
-110,163 Reduced 70.55%
45,995 $56,000
Q2 2020

Aug 14, 2020

BUY
$1.69 - $4.2 $244,543 - $607,740
144,700 Added 1262.87%
156,158 $269,000
Q1 2020

May 15, 2020

SELL
$1.26 - $3.38 $3,143 - $8,433
-2,495 Reduced 17.88%
11,458 $30,000
Q3 2019

Nov 14, 2019

SELL
$1.21 - $1.59 $3,188 - $4,189
-2,635 Reduced 15.88%
13,953 $17,000
Q2 2019

Aug 14, 2019

BUY
$1.25 - $3.14 $43 - $109
35 Added 0.21%
16,588 $25,000
Q1 2019

May 15, 2019

SELL
$2.79 - $4.09 $20,925 - $30,675
-7,500 Reduced 31.18%
16,553 $49,000
Q4 2018

Feb 14, 2019

BUY
$3.23 - $7.01 $77,691 - $168,611
24,053 New
24,053 $81,000
Q3 2018

Nov 14, 2018

SELL
$6.86 - $9.97 $95,861 - $139,320
-13,974 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$2.88 - $8.67 $40,245 - $121,154
13,974 New
13,974 $96,000
Q4 2017

Feb 14, 2018

SELL
$2.99 - $4.85 $86,680 - $140,601
-28,990 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$3.01 - $5.41 $87,259 - $156,835
28,990
28,990 $136,000

Others Institutions Holding VSTM

About Verastem, Inc.


  • Ticker VSTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 210,000,000
  • Market Cap $1.09B
  • Description
  • Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...
More about VSTM
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.